Skip to main content

MaxCyte, Inc. (MXCT)

NASDAQ: MXCT · IEX Real-Time Price · USD
14.25 0.00 (0.00%)
Sep 22, 2021 12:46 PM EDT - Market open
Market Cap983.32M
Revenue (ttm)26.92M
Net Income (ttm)-15.86M
Shares Out69.00M
EPS (ttm)-0.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume121,992
Open14.50
Previous Close0.00
Day's Range14.14 - 14.80
52-Week Range0.00 - 14.80
Beta0.99
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About MXCT

MaxCyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Cell therapy has emerged as one of the fastest growing and most promising treatment modalities to address a host of human diseases....

IndustryDiagnostics & Research
IPO DateJul 30, 2021
CEODoug Doerfler
Employees65
Stock ExchangeNASDAQ
Ticker SymbolMXCT
Full Company Profile

Financial Performance

In 2020, MaxCyte's revenue was $26.17 million, an increase of 21.04% compared to the previous year's $21.62 million. Losses were -$11.82 million, -8.36% less than in 2019.

Financial Statements

News

MaxCyte Set to Join Russell 2000® Index

GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to...

5 days ago - GlobeNewsWire

MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections

GAITHERSBURG, Md., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to...

1 week ago - GlobeNewsWire

MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced t...

2 weeks ago - GlobeNewsWire

Tuesday Afternoon Analyst Upgrades and Downgrades: Palo Alto Networks, Victoria's Secret and More

With the trading day more than halfway over, the broad markets were seeing another round of gains on Tuesday.

Other symbols:PANWVSCOBILIOMGAPACK
4 weeks ago - 24/7 Wall Street

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

GAITHERSBURG, Md., Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical an...

1 month ago - PRNewsWire

London-Listed MaxCyte Makes NASDAQ Debut Today

MaxCyte Inc (NASDAQ: MXCT) is already trading on London's AIM, but now, it debuted on NASDAQ after pricing a $176 million IPO at $13 apiece, on the higher end of an $11.50 to $13.50 range. The Company o...

1 month ago - Benzinga

DLA Piper advises underwriters of MaxCyte's upsized US IPO

NEW YORK, July 30, 2021 /PRNewswire/ -- DLA Piper represented Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C., as underwriters in the initial US publ...

1 month ago - PRNewsWire

MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market

GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized offering of 13...

1 month ago - PRNewsWire

MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing

GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering, today announced the public filing of a registra...

2 months ago - PRNewsWire

MaxCyte IPO Registration Document (S-1)

MaxCyte, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC